Verified peer comparison

REGN vs AMGN

Regeneron Pharmaceuticals, Inc. compared with Amgen Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

REGN

Regeneron Pharmaceuticals, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

AMGN

Amgen Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

REGN: Biotechnology

AMGN: Biotechnology

Upside lens

REGN: New indications, age groups and geographies can extend a broad type-2 inflammation franchise. Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry. Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

AMGN: Broad volume growth across Repatha, EVENITY, rare-disease and oncology products can offset declines in mature brands. MariTide and other Phase 3 programs can create new growth franchises if clinical and regulatory milestones succeed. Expansion of UPLIZNA, IMDELLTRA and other newer medicines can diversify product growth.

Risk lens

REGN: Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share. Profit-sharing and dependence on collaborators shape the cash economics of major products. Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

AMGN: Competition is accelerating declines in Prolia, XGEVA and other established products. Medicare price setting, 340B mix, payer pressure and global reforms can reduce net selling prices. Clinical failures can impair growth expectations while acquisition-related debt and commitments limit flexibility.